MedPath

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

Phase 2
Completed
Conditions
Schizophrenia
Registration Number
NCT00036127
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

Study to learn if the alternate formulation is effective in agitated schizophrenic patients

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Agitated schizophrenic patients
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Local Institution

πŸ‡ΊπŸ‡Έ

Milwaukee, Wisconsin, United States

Local Instituton

πŸ‡ΊπŸ‡Έ

Hoffman Estates, Illinois, United States

Local Institution
πŸ‡ΊπŸ‡ΈMilwaukee, Wisconsin, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.